Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of linerixibat for cholestatic pruritus in primary biliary cholangitis
MOH_2022-08-02_011953Phase 3Recruiting
- Sponsor
- GSK
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cholestatic pruritus and primary biliary cholangitis (PBC) comparing linerixibat with placebo (2 arms). Primary endpoint: Not reported. Started May 2022; status: recruiting.
02
Drugs
linerixibat
03
Conditions
cholestatic pruritusprimary biliary cholangitis (PBC)
Beyond the preview
Go deeper on MOH_2022-08-02_011953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-02_011953.